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British Columbia, Vancouver, BC, Canada; cCentre for Regenerative Medicine and Stem Cell Research, Aga Khan University, Karachi, Pakistan; dDanish 
Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; eDepartment of Surgical Pathology, 
Zealand University Hospital, Roskilde, Denmark; fDepartment of Oncology, Herlev and Gentofte, University of Copenhagen, Herlev, Denmark; 
gDepartment of Pathology and Laboratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada
ABSTRACT
Preclinical studies suggest that some effects of conventional chemotherapy, and in particular, gemcita-
bine, are mediated through enhanced antitumor immune responses. The objective of this study was to 
use material from a randomized clinical trial to evaluate whether patients with preexisting immune 
infiltrates responded better to treatment with gemcitabine + docetaxel (GD) compared to docetaxel 
alone. Formalin fixed, paraffin-embedded breast cancer tissues from SBG0102 phase 3 trial patients 
randomly assigned to treatment with GD or docetaxel were used. Immunohistochemical staining for 
CD8, FOXP3, LAG3, PD-1, PD-L1 and CD163 was performed. Tumor infiltrating lymphocytes (TILs) and 
tumor associated macrophages were evaluated. Prespecified statistical analyses were performed in 
a formal prospective-retrospective design. Time to progression was primary endpoint and overall survival 
secondary endpoint. Correlations between biomarker status and endpoints were evaluated using the 
Kaplan–Meier method and Cox proportional hazards models. Biomarker data was obtained for 237 
patients. There was no difference in treatment effect according to biomarker status for the whole cohort. 
In planned subgroup analysis by PAM50 subtype, in non-luminal (basal-like and HER2E) breast cancers 
FOXP3 was a significant predictor of treatment effect with GD compared to docetaxel, with a HR of 0.22 
(0.09–0.52) for tumors with low FOXP3 compared to HR 0.92 (0.47–1.80) for high FOXP3 TILs (Pinteraction 
= 0.01). Immune biomarkers were not predictive of added benefit of gemcitabine in a cohort of mixed 
breast cancer subtypes. However, in non-luminal breast cancers, patients with low FOXP3+ TILs may have 
significant benefit from added gemcitabine.
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Introduction
Globally, breast carcinoma is the most common malignancy 
amongst women and accounts for more than two million new 
cases diagnosed each year. Despite targeted treatment options 
and the relatively high efficacy of conventional chemotherapy, 
breast cancer remains responsible for 15% of all cancer deaths 
in women.1 The basal-like/triple-negative (TNBC) subtype of 
breast cancer remains the most challenging, as there are cur-
rently few treatment options beyond conventional 
chemotherapy.12,3
In recent years, the importance of the immune microenvir-
onment surrounding cancer cells has gained increasing interest 
with the advent of immunotherapy and the discovery of the 
significance of an activated immune system for the prognosis 
of cancer.4–6 In breast cancer, most research has been centered 
around basal-like/TNBC or HER2 positive subtypes, as these 
are often characterized by a pronounced inflammatory infil-
trate that has shown clear positive prognostic significance.7,8 In 
this context, it has been shown that tumor infiltrating 
lymphocytes and particularly the CD8 positive cytotoxic 
T-cell subset are important for immune-mediated tumor cell 
death.9
PD-L1 inhibitor immune therapy in combination with nab- 
paclitaxel for advanced TNBC has recently been approved.10,11 
However, as breast carcinoma is not one of the most immuno-
genic forms of cancer, the search continues for effective 
approaches to augment the immune response by priming 
tumors for immune therapy.2,12 Conventional chemotherapy 
may play a role in this, as several agents have shown relevant 
off-target effects on both the innate and adaptive immune 
systems.2,13,14 Potentiating effects can be mediated through 
immunogenic tumor cell death, changes in IFN-γ and inter-
leukin release, novel antigen presentation, and post-treatment 
replenishment of the lymphocyte pool with potential replace-
ment of regulatory and exhausted phenotype T-cells.2,13,14 
Multiple clinical trials have investigated or are investigating 
the advantages of adding conventional backbone chemother-
apy to immunotherapy; several of these have shown promising 
improvements in survival of patients receiving both 
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chemotherapy and immunotherapy compared to patients 
receiving only monotherapy2,15. Thesignificance of which che-
motherapy drug should be combined with immune therapy has 
recently been discussed in the context of the Impassion 130 
trial combining the PD-L1 inhibitor atezolizumab with nab- 
paclitaxel,11 and the subsequent Impassion 131 trial combining 
atezolizumab with paclitaxel.16 Where the first study led to the 
approval of atezolizumab for TNBC, the second trial has not 
yet shown significant results. It is a matter for discussion 
whether this could be due to a greater use of steroids in the 
latter trial as a prerequisite for use with paclitaxel, differences 
in the delivery of nab-paclitaxel and paclitaxel in the tumor 
microenvironment or even due to TNBC heterogeneity.17 
Within TNBC as a category, the immune activated subtype 
represents a composition of microenvironments defined by 
factors beyond PD-L1 expression that could explain the differ-
ences in immunotherapy response between the two trials. In 
view of the negative results of the IMpassion-131 trial, it is 
currently recommended to use the combination of nab- 
paclitaxel with atezolizumab in metastatic TNBC.18
Docetaxel and gemcitabine are among the forms of conven-
tional cytotoxic chemotherapy that have effects on the tumor 
immune microenvironment (TME). In preclinical models, 
both drugs induce changes in the TME by modulating innate 
and adaptive immune responses, leading to an increased sus-
ceptibility to immune mediated cell death.13,19–27 Gemcitabine 
in particular seems to enhance T-cell activation in pre-clinical 
studies. Changes in the TME following gemcitabine treatment 
include inhibition of myeloid-derived suppressor cells, leading 
to more activated cytotoxic T-cells, naïve T-cell activation, and 
upregulation of natural killer cells along with changes in 
macrophage polarization.22,24,28 Clinically, studies have sug-
gested that an immune-active environment may predict che-
motherapy efficacy including regimes containing taxanes or 
gemcitabine.29 However, the predictive capacity of the TME 
for benefit from gemcitabine treatment, alone or in combina-
tion with docetaxel, has not yet been investigated in a setting 
involving randomized clinical trials of breast cancer.
For this study, we used the Danish SBG0102 phase III 
clinical trial, which randomized patients with advanced breast 
cancer to receive either docetaxel or gemcitabine + docetaxel 
(GD). The original trial did not find a survival benefit of GD 
over docetaxel alone.30 However, subsequent post-hoc analy-
sis using the PAM50 assay showed a large survival advantage 
in the GD group amongst patients with basal-like breast 
cancer.31 As the basal-like subtype is the most immune- 
active intrinsic subtype of breast cancer,32 we investigated 
whether the added benefit of gemcitabine, an immunostimu-
latory form of chemotherapy, correlated with more active 
immune responses in the primary tumor. As biomarkers for 
an activated immune response, we assessed CD8 as our pri-
mary T-cell marker; stromal tumor infiltrating lymphocytes 
(TILs); and immunosuppressive biomarkers including PD-1 
(programmed cell death protein 1), PD-L1 (programmed 
death ligand 1), LAG3 (lymphocyte activation gene 33),and 
FOXP3 (forkhead box protein 3) were also investigated. 
Additionally, as a marker for the innate immune system, we 
investigated the predictive capacity of CD163 expressing 
tumor associated macrophages.
Material and methods
Study population and design
The present study is based on surgical material from patients 
enrolled in the Danish Breast Cancer Group (DBCG) rando-
mized clinical trial SBG0102. In this trial, patients with locally 
advanced or metastatic breast cancer were randomized to 
receive either docetaxel or docetaxel + gemcitabine. A total of 
337 women were included in the trial. Patients received either 
docetaxel (100 mg/m2) on day 1 every 21 days, or gemcitabine 
(1000 mg/m2) on days 1 and 8 and docetaxel (75 mg/m2) 
on day 8 every 21 days. A detailed description of the study 
including eligibility criteria and study results has been pub-
lished previously.30 No patients had received neoadjuvant che-
motherapy prior to inclusion.
The original study and subsequent supplementary biomar-
ker studies were approved by the Danish National Committee 
on Biomedical Research Ethics [KF12-315,632 (August 2006)/ 
H-KF-02-045-01 (June 2007)/H-190131109 (June 2019) with 
additional approval 77987 (March 2021)].
The study was designed in accordance with the reporting 
recommendations for tumor marker prognostic studies 
(REMARK).33 Based on this, our group performed a test of 
the prespecified hypothesis that a preexisting immune 
response, as defined by the expression of specific immune 
response biomarkers in primary breast cancer tumor tissue, 
predicts superior time to progression and overall survival in 
advanced breast cancer patients, when randomized to 
a treatment regime containing both gemcitabine and docetaxel 
as compared to (higher dose) docetaxel alone.
As our primary biomarker, we selected CD8 positive intra-
tumoral tumor infiltrating lymphocytes (TILs), as this biomar-
ker mainly identifies the cytotoxic T-cell subset, shown to be 
a major effector of antitumor immune interactions and to carry 
prognostic significance in several studies.34–37 For secondary 
analyses, we also selected well-described immune checkpoint 
molecules including PD-1, PD-L1, and LAG3. FOXP3 was 
assessed, as a marker for regulatory T-cells associated with 
dampening immune responses.38 Supplementary, CD163, 
a macrophage marker, was assessed for predictive capacity.39
Analyses were carried out on the whole cohort, and as 
a preselected subgroup analysis on the non-luminal breast 
cancers, a category combining the basal-like and HER2- 
enriched (HER2E) PAM50 subtypes based on published 
research showing these two subtypes to be similar in their 
tumor-immune microenvironment.7,32 Tests for heterogeneity 
of prognostic significance in luminal subtypes (luminal A and 
luminal B) versus non-luminal subtypes were also performed.
Study material and immunohistochemical staining
In this study, we utilized 11 previously constructed tissue 
microarray (TMA) blocks containing formalin fixed, paraffin- 
embedded primary tumor tissue from 276 patients enrolled in 
the SBG0102 study, provided by the DBCG Tumor Tissue Data 
Repository. The TMAs contain two 2 mm cores of primary 
breast cancer tissue per patient, as previously described.40 
Immunohistochemical (IHC) staining for CD8 (clone C8/ 
144B, Dako), PD-1 (clone NAT105, CellMarque), LAG3 
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(clone 17B4, Abcam), FOXP3 (clone 236A/E7, Abcam) and 
CD163 (clone 10D6, Leica Biosystems) was performed as per 
manufacturer’s protocol using the Ventana Discovery Ultra 
staining platform at the Genetic Pathology Evaluation Center 
(Vancouver, Canada). PD-L1 staining using the SP142 clone 
(Roche) was performed following manufacturer’s instructions 
at the Victoria Deeley Research Center (Victoria, Canada).
Staining and scoring of the standard breast cancer biomar-
kers ER, PR, and HER2 had been performed in connection 
with previous publications following published methods at the 
Genetic Pathology Evaluation Center, Vancouver, Canada.40–43
Slides were scanned and digitized on the Aperio AT2 scan-
ner at 20X magnification. Representative photomicrographs 
are shown in supplementary Figure S1.
Biomarker assessment
Biomarker assessment was performed by two experienced 
pathologists, DG (CD8, PD-1, FOXP3, LAG3 and CD163) 
and ES (TILs and PD-L1). Difficult cases were discussed 
between the two pathologists and consensus was reached. 
The two pathologists did not have access to clinical data 
when scoring the biomarkers.
For CD8, LAG3, PD-1 and FOXP3, scoring data were cap-
tured for stromal TILs (sTILs) and intratumoral TILs (iTILS). 
As previously published, sTILs were defined as TILs present in 
the peritumoral stroma, not in direct contact with carcinoma 
cells. iTILs were defined as TILs in direct contact with carci-
noma cells. This strategy was chosen as TILs in the intratu-
moral and stromal compartment have been shown to exhibit 
different prognostic associations.44,45
For CD163, membranous or cytoplasmic expression on 
tumor-associated macrophages was scored as previously 
described.46
CD8, LAG3, FOXP3 and PD-1 iTILs and sTILs and CD163 
positive macrophages were reported as an absolute count in 
one TMA core, or in cases where two interpretable cores were 
available, the mean of the absolute counts in the two TMA 
cores corresponding to each patient. Cutpoints for biomarker 
positivity were locked down prior to clinical data analysis. For 
CD8, cutpoints that had been previously established and vali-
dated on a large cohort were used.44 As the previous cohort 
used 0.6 mm cores, cutoffs were expanded by a factor 10 to 
account for the increased area of the 2 mm cores used in this 
study. For CD8 iTILs, the adjusted cutoffs were ≤10 vs >10; for 
CD8 sTILs cutoffs were ≤30 vs >30. For LAG3 and PD-1, we 
followed our previous publications on lymphocyte biomarkers 
and set cutoffs to dichotomize between no expression and any 
expression (0 vs > 0) both for iTILs and sTILs.47,48 FOXP3 
iTILs cutoff was set to <2 vs ≥2 and cutoff for FOXP3 sTILs was 
<3 vs ≥3.48 The cutoffs for CD163 expressing tumor associated 
macrophages were also adjusted from studies in our previous 
cohort and were set to <56 vs ≥56.39
PD-L1 scoring was performed according to manufacturer’s 
guidelines as area of PD-L1 positive TILs out of total tumor 
area.49 A cutoff of ≥1% for positive expression was used when 
relevant, as this is the commonly used cutoff for clinical trials 
and treatment indications.10 When relevant, PD-L1 was also 
tested as a continuous variable.
TILs were assessed on hematoxylin-eosin (HE) stained slides, 
according to the extensively validated guidelines published by 
the International Immuno-Oncology Biomarker working 
group. Briefly, TILs were scored as the percentage of intratu-
moral stroma occupied by lymphocytes.9 The median preva-
lence of TILs in our cohort was used as cutoff (≤1% vs >1%). 
When relevant, TILs were also tested as a continuous variable.
PAM50 intrinsic subtyping
PAM50 intrinsic subtyping using the Nanostring nCounter 
system on the SBG0102 material has been published pre-
viously, including a detailed description of RNA extraction, 
Nanostring nCounter processing and data analysis.31
Statistical analysis
Statistical analysis was performed by the DBCG according to 
a written prespecified plan. Descriptive statistics were utilized 
to summarize patient characteristics. Differences in patient 
characteristics between biomarker groups were assessed with 
chi-squared test or Fishers exact test, excluding unknowns.
As in the original trial, the primary endpoint was time to 
progression (TTP) and secondary endpoint overall survival 
(OS). TTP was defined as the time from random assign-
ment to date of progression with censoring at last visit date 
or death. Complete follow-up on vital status data until 
July 1st, 2020 was ensured through linkage to the Danish 
Civil Registration System (CPR). OS was defined as the 
time elapsed from random assignment until death from 
any cause.
TTP and OS rates were estimated according to the 
Kaplan–Meier method. The effects of the biomarker groups 
(low vs. high) and biomarkers as continuous variables per 
10%-point increase on TTP and OS were quantified in 
terms of hazard ratios (HRs) with 95% confidence intervals 
(CI) and estimated unadjusted and adjusted using Cox 
proportional hazard models. Biomarkers were assessed indi-
vidually, i.e. in separate models.
In multivariate analysis, the following variables were 
considered: PAM50 subtype, ECOG performance status 
(0–1 vs 2), visceral disease (yes vs no), age (<50 vs ≥ 50), 
stage of disease (locally advanced vs metastatic), number of 
metastatic sites (<3 vs ≥ 3) and treatment regime. Variables 
with statistical significance were included in the final multi-
variate models. Tests for proportional hazards were 
assessed by Schoenfeld residuals models. The Wald test 
for interaction between biomarker expression groups and 
subtype (luminal vs non-luminal) or treatment arm was 
used to evaluate differences between subgroups and predic-
tive effects, respectively.
All tests were two-sided with a significance level of 0.05, 
unadjusted for number of comparisons.
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All statistical analyses were performed with the use of SAS 
software, version 9.4 (SAS Institute, Cary, NC, USA).
Results
Clinicopathological characteristics and biomarker 
expression
Biomarker assessment was available in 237 out of the 276 
patients with TMA available. In 39 cases, biomarker assess-
ment was not possible due to insufficient tissue remaining in 
the core, or too few invasive breast cancer cells present. Out of 
the 237 patients, IHC assessment of CD8 was possible in 234 
cases, 233 cases for FOXP3, 230 cases for LAG3, 231 cases for 
PD-1, 219 cases for PD-L1 and 224 cases for CD163. TIL 
evaluation on HE slides was possible in 216 cases. Out of the 
237 patients with IHC scores, 5 patients did not have PAM50 
information available. A flow diagram of the study cohort is 
presented in Supplementary Figure S2.
The group of patients available for biomarker assessment 
differed from the excluded group wwith regard toprior che-
motherapy regimens (anthracyclines vs non-anthracyclines) 
and radiotherapy (P < .05) (data not shown). This is most likely 
due to patients with locally advanced disease, as these patients 
more often only had a needle biopsy available for testing, 
resulting in tissue being unavailable or with too few tumor 
cells for testing. The excluded group did not differ from the 
included group in other parameters. Patient characteristics 
according to treatment allocation have been previously 
described for the whole cohort30 and can be seen in 
Supplementary Table S1 for the cohort used in this study.
We found high CD8 iTIL expression in a total of 80 patients 
(34%); the median absolute count was 7 per 2 mm tissue core. 
High CD8 sTIL expression was seen in 182 patients (78%) with 
a median of 100. Patient characteristics according to CD8 iTILs 
can be seen in Supplementary Table S3. Neither CD8 iTIL nor 
sTIL expression were significantly associated with the subtype 
(Table 1) or hormone receptor status (Supplementary Table 
S3) in this data set of primary tumor tissue samples from 
patients who developed advanced disease. CD8 positivity was 
also not associated with any other relevant clinicopathological 
characteristics.
Median absolute counts per core were 1 for FOXP3 iTILs, 
12 for FOXP3 sTILs, and 0 for LAG3 and PD-1 (iTILs or 
sTILs). Median PD-L1 expression was 0, and median HE 
TILs were 1%. Median CD163 positive cell count (macro-
phages) was 46. Associations of biomarkers with PAM50 sub-
types are presented in Table 1. Expression of FOXP3, LAG3, 
PD-1, PD-L1, and HE TIL counts were all associated with 
PAM50 subtypes (P < .05). For all of them, a higher percentage 
of positive expression was seen in the basal-like and HER2 
enriched subtypes. PD-1, LAG3 and FOXP3 iTILs were also 
associated with ER negativity (data not shown).
For the whole cohort, total number of events were 231 for 
OS and 176 for TTP. For the non-luminal subtypes (basal-like 
+ HER2E), there were 74 events for OS and 59 events for TTP.
In multivariate analysis of the study, PAM50 subtype, 
ECOG performance status (0–1 vs 2) and visceral disease (yes 
vs. no) were found to be significant for OS. Treatment with 
combination therapy (GD) was associated with significantly 
longer TTP compared to monotherapy with docetaxel. 
Likewise, PAM50 subtypes were significantly associated with 
TTP. Hazard ratios for all significant variables are presented in 
Supplementary Table S2.
Prognostic value of immune biomarkers in SBG0102 
advanced breast cancers
In the whole cohort, CD8 iTILs were not prognostic for either 
TTP or OS in uni- or multivariate analysis (Table 2, Figure 1a 
and b, Supplementary Figure S3, A-B and Supplementary Table 
S4). In a test of heterogeneity for differential effect in the 
luminal and non-luminal subtypes (basal like and HER2E 
together, 76 patients), there was a lower HR for OS for the 
CD8 iTILs high group in univariate analysis (HR 0.69 [95%CI 
0.43–1.11], vs HR 1.28 [0.91–1.81] for luminal cases, Pinteraction 
= 0.04). This was not preserved in multivariate analysis (0.70 
[0.43–1.13] vs HR 1.21 [0.84–1.74], Pinteraction = 0.08) 
(Supplementary Table S5).
While we had chosen intratumoral TILs as our primary 
mode of assessment of CD8 as we had in other studies,44,50 
stromal CD8+ TILs were also assessed. CD8 sTILs did not 
show prognostic significance for the whole cohort. However, 
in a test of heterogeneity of effect in the luminal and nonlum-
inal subtypes, there was also a trend toward a lower HR for 
TTP in the CD8 sTILs high non-luminal subtypes than in the 
CD8 sTILs high luminal subtypes (HR 0.46 [0.24–0.86] for 
non-luminal subtypes vs HR 1.00 [0.63–1.58] for luminal 
Table 1. Correlations of investigated biomarkers with PAM50 subtypes (n = 232).
Total [n (%)] Luminal A [n (%)] Luminal B [n (%)] Basal like [n (%)] HER2E [n (%)] P
Biomarker Low High Low High Low High Low High Low High
CD8 iTILs count ≤10 vs >10 150 (66) 79 (34) 54 (76) 17 (24) 51 (62) 31 (38) 17 (52) 16 (48) 28 (65) 15 (35) 0.08
CD8 sTILs count ≤30 vs >30 51 (22) 178 (78) 13 (18) 58 (82) 21 (26) 61 (74) 9 (27) 24 (73) 8 (19) 35 (81) 0.58
FOXP3 iTILs count <2 vs ≥2 132 (58) 95 (42) 54 (77) 16 (23) 47 (58) 34 (42) 9 (27) 24 (73) 22 (51) 21 (49) <0.0001
FOXP3 sTILs count <3 vs ≥3 58 (26) 169 (74) 29 (41) 41 (59) 21 (26) 60 (74) 3 (9) 30 (91) 5 (12) 38 (88) 0.0004
LAG3 iTILs count 0 vs ≥1 188 (84) 37 (16) 66 (96) 3 (4) 71 (89) 9 (11) 18 (55) 15 (45) 33(77) 10 (23) <0.0001
LAG3 sTILs count 0 vs ≥1 143 (64) 82 (36) 57 (83) 12 (17) 52 (65) 28 (35) 13 (39) 20 (61) 21 (49) 22 (51) <0.0001
PD-1 iTILs count 0 vs ≥1 181 (80) 45 (20) 63 (91) 6 (9) 65 (79) 17 (21) 20 (63) 12 (38) 33 (77) 10 (23) 0.007
PD-1 sTILs count 0 vs ≥1 127 (56) 99 (44) 44 (64) 25 (36) 54 (66) 28 (34) 10 (31) 22 (69) 19 (44) 24 (56) 0.002
PD-L1 < 1% vs ≥1% 185 (87) 28 (13) 63 (98) 1 (2) 66 (88) 9 (12) 22 (69) 10 (31) 34 (81) 8 (10) 0.0004
HE TILs ≤1% vs >1% 135 (64) 76 (36) 45 (71) 18 (29) 55 (71) 22 (29) 15 (49) 17 (53) 20 (51) 19 (49) 0.02
CD163 TAM <56 vs ≥56 132(46.5) 92 (32.4) 41(63.1) 24 (36.9) 58(73.4) 21 (26.6) 6(18.8) 26 (81.2) 23 (59) 16 (41) <0.001
Numbers of patients are shown and percentages of the given subtype in parentheses. Cases with missing biomarker scores not shown. iTILs: intratumoral tumor 
infiltrating lymphocytes, sTILs: stromal tumor infiltrating lymphocytes, HE: hematoxylin-eosin; TAM: tumor associated macrophages.
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subtypes, Pinteraction = 0.06) in univariate analysis. The same 
was seen in multivariate analysis (Supplementary Table S5). 
CD8 sTILs also showed a trend for improved OS in the non- 
luminal subtypes in univariate analysis, although this was not 
significant (HR 0.65 [0.38–1.12]) (Supplementary Figure S4) .
FOXP3 iTILs, PD-1, LAG3 iTILs and HE TILs also did not 
show prognostic significance when looking at the whole cohort 
in univariate analysis (Table 2). LAG3 sTILs did show prog-
nostic significance for OS in univariate analysis (HR 1.46 [1.-
11–1.93]), and PD-L1 high expression was significant for TTP 
in univariate analysis (HR 1.59 [1.03–2.44]); however, these 
effects were not retained in multivariate analysis 
(Supplementary Table S4). FOXP3 sTILs were not significant 
for TTP in univariate analysis; however, in multivariate analy-
sis including PAM50 subtypes and treatment regime, high 
FOXP3 sTILs were significant for TTP (HR 0.67 [0.46–0.98], 
P = .04). This was mainly driven by adjustment for PAM50 
subtypes (TTP for LAG3 iTILs when only adjusted for PAM50 
subtypes: HR: 0.63 [0.44–0.93]; TTP when only adjusted for 
treatment HR 0.93 [0.66–1.31]).
In the planned subgroup analysis of the non-luminal and 
luminal subtypes, FOXP3, PD-1, PD-L1, LAG3 and HE TILs 
did not impact survival in either uni- or multivariate analysis, 
and there was no differential effect in luminal and non-luminal 
subtypes (Supplementary Table S5).
Predictive value of immune biomarkers for gemcitabine + 
docetaxel vs. docetaxel monotherapy
There were no significant differences in treatment effect 
according to CD8 iTIL status for patients treated with doce-
taxel or GD for the primary endpoint of TTP or the secondary 
endpoint of OS (Figure 1c and d, Table 3).
For CD163, there were no significant differences for TTP 
(Table 3). However, patients with high expression benefitted 
significantly more from GD than from docetaxel in univariate 
analysis of OS (HR for low expression 1.16 [CI:0.81–1.65], HR 
Table 2. Prognostic hazard ratios in the overall cohort for high vs low levels of 
immune biomarkers in univariate analysis.
Biomarker (High vs Low)
HR (95% CI)
TTP P OS P
CD8 iTILs count ≤10 vs >10 1.04 (0.76–1.43) 0.81 1.10 (0.83–1.44) 0.51
CD8 sTILs count ≤30 vs >30 0.86 (0.60–1.24) 0.43 1.00 (0.73–1.37) 0.99
FOXP3 iTILs count <2 vs ≥2 0.99 (0.74–1.34) 0.96 1.21 (0.93–1.58) 0.15
FOXP3 sTILs count <3 vs ≥3 0.90 (0.64–1.25) 0.52 1.00 (0.74–1.34) 0.97
LAG3 iTILs count 0 vs ≥1 1.42 (0.95–2.14) 0.09 1.28 (0.90–1.82) 0.17
LAG3 sTILs count 0 vs ≥1 1.22 (0.89–1.67) 0.21 1.46 (1.11–1.93) 0.01
PD-1 iTILs count 0 vs ≥1 1.39 (0.97–1.96) 0.07 1.04 (0.75–1.45) 0.80
PD-1 sTILs count 0 vs ≥1 1.17 (0.87–1.57) 0.31 0.93 (0.71–1.21) 0.58
PD-L1 < 1% vs ≥1% 1.59 (1.03–2.44) 0.04 1.47 (0.98–2.20) 0.06
HE TILs ≤1% vs >1% 1.06 (0.78–1.45) 0.71 1.03 (0.78–1.37) 0.82
Abbreviations: HR: hazard ratio, TTP: time to progression, OS: overall survival, iTILs: 
intratumoral tumor infiltrating lymphocytes, sTILs: stromal tumor infiltrating 
lymphocytes, HE: hematoxylin-eosin.
Figure 1. Time to progression (TTP) and associations with CD8 levels in the SBG0102 trial population. A. CD8 iTILs and TTP in the overall cohort, B. CD8iTILs and TTP in 
the non-luminal (BL and HER2E) subtypes C. TTP for the CD8 iTILs low group, stratified by treatment with docetaxel or docetaxel +gemcitabine (DG) D. TTP for the CD8 
iTILs high group, stratified by treatment with docetaxel or DG. Corresponding figures for overall survival can beseen in Supplementary Figure S3. iTILs: intratumoral 
tumor infiltrating lymphocytes.
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for high expression 0.63 [0.41–0.96], Pinteraction = 0.03). 
However, this effect was not significant in multivariate analysis 
(HR for low expression 1.09 [CI:0.76–1.58], HR for high 
expression 0.62 [0.40–0.96], Pinteraction = 0.051)
None of the other biomarkers investigated were predictive 
of treatment effect when looking at the whole cohort (see Table 
3 and Figure 2a and b).
We also performed subgroup analyses of CD8 iTILs and 
sTILs, FOXP3 iTILs and CD163 in the non-luminal subtypes 
(basal + HER2E). Low FOXP3 iTILs were found to benefit 
significantly more from GD than from docetaxel alone with 
aanHR of 0.22 (CI: 0.09–0.52) for low FOXP3 iTILs compared 
to HR 0.92 (CI: 0.47–1.80) for high FOXP3 iTILs (Pinteraction 
= 0.01) for TTP (Figure 2c and d, Supplementary Figure S5). 
CD8 status and CD163 were not predictive in the non-luminal 
subgroup analysis.
Discussion
In the SBG0102 clinical trial randomizing patients with 
advanced breast cancer to receive either docetaxel or docetaxel 
+ gemcitabine, we found that CD8 positive TILs were not 
prognostic for the overall cohort but did show some prognostic 
significance in the non-luminal subtypes. These results align 
well with what we expected, as TILs in ER positive subtypes do 
not carry prognostic significance to the same degree as they do 
in the ER negative subset.51 CD8 TILs and our other biomar-
kers of adaptive immunity also did not have predictive value 
for benefit from gemcitabine in the whole cohort. The macro-
phage marker CD163 did give some indication of a possible 
significant predictive effect for OS. Studies have shown that 
docetaxel and gemcitabine modulate the innate immune sys-
tem including macrophages and myeloid-derived suppressor 
cells in both stimulatory and inhibitory ways.19,20,24 Taken 
together with results of our study, further research on the 
predictive capacity of markers of the innate immune system 
is warranted in prospective cohorts treated with immune mod-
ulating chemotherapies.
In the subgroup analysis of the non-luminal subtypes, where 
the degree of immune response should be most significant for 
outcome, we also found that CD8 TILs were not predictive for 
benefit from gemcitabine. In this group, we did, however, find 
that patients with low FOXP3 levels benefitted more from GD 
than from docetaxel alone. The FOXP3 positive subset of 
T-lymphocytes are also known as regulatory T-cells, and func-
tion as negative regulators of CD8 positive cytotoxic T-cells, 
thereby contributing to a dampening of the immune response 
to tumor cells. Some chemotherapeutic drugs have been shown 
to specifically deplete regulatory T-cells,28,52 so in patients with 
already low levels of FOXP3 regulatory T-cells, this might 
mean that the inhibitory effect of these cells could become 
almost totally removed. Our results could signify that patients 
with low levels of regulatory T-cells do benefit from the addi-
tion of another chemotherapeutic drug that contributes to a net 
immunostimulatory effect. However, events were few in this 
exploratory analysis and our results should be tested in a larger 
cohort. Although most studies on the effect of docetaxel and 
gemcitabine on the TME have shown a stimulating effect, some 
pre-clinical studies have instead shown a detrimental effect on 
the efficacy of immune eradication of cancer cells with treat-
ment with either docetaxel or gemcitabine. Debangshu eet al. 
showed that treatment with taxanes induced the T-cell inhibi-
tory biomarkers PD-L1 and CD73 and macrophage inhibiting 
CD47 on breast cancer cells.53 An inhibitory effect on natural 
killer cells by docetaxel has also been shown.54 One possible 
explanation for our inability to identify a benefit from gemci-
tabine in tumors with CD8 high expression is that co- 
treatment with docetaxel may have canceled out any immune 
stimulatory effects.
Nevertheless, giving taxanes together with immunotherapy 
has already been shown to benefit the TNBC subset of patients 
and seems to be more beneficial than giving immunotherapy 
alone. The Impassion 130 trial, which led to FDA-approval of 
the PD-L1 inhibitor atezolizumab, combined nab-paclitaxel 
with atezolizumab, for first-line treatment of unresectable, 
locally advanced or metastatic breast cancer patients. This 
study has reported improved survival in the PD-L1 positive 
Table 3. Predictive hazard ratios for treatment effect for TTP in patients treated with docetaxel + gemcitabine vs docetaxel alone. Values shown for multivariate analysis 
for the whole subset, and for the focused set of analyses performed on the non-luminal subset a Basal like + HER2E.





PinteractionLow High Low High
CD8 iTILs count ≤10 vs >10 0.71 (0.49–1.02) 0.73 (0.43–1.22) 0.93 0.42 (0.21–0.81) 0.76 (0.33–1.74) 0.27
CD8 sTILs count ≤30 vs >30 0.80 (0.45–1.40) 0.70 (0.51–0.96) 0.79 0.31 (0.10–1.02) 0.63 (0.35–1.13) 0.29
FOXP3 iTILs count <2 vs ≥2 0.59 (0.39–0.89) 0.88 (0.56–1.38) 0.21 0.22 (0.09–0.52) 0.92 (0.47–1.80) 0.01
FOXP3 sTILs count <3 vs ≥3 0.76 (0.41–1.40) 0.72 (0.51–1.02) 0.87
LAG3 iTILs count 0 vs ≥1 0.69 (0.50–0.96) 0.77 (0.37–1.63) 0.79
LAG3 sTILs count 0 vs ≥1 0.71 (0.48–1.04) 0.69 (0.42–1.13) 0.96
PD-1 iTILs count 0 vs ≥1 0.68 (0.48–0.96) 0.88 (0.47–1.67) 0.48
PD-1 sTILs count 0 vs ≥1 0.75 (0.49–1.14) 0.66 (0.42–1.02) 0.66
PD-L1 < 1% vs ≥1% 0.68 (0.48–0.95) 0.85 (0.39–1.88) 0.60
HE TILs ≤1% vs >1% 0.66 (0.45–0.98) 0.90 (0.54–1.48) 0.35
CD163 TAM <56 vs ≥56 0.72 (0.47–1.10) 0.51 (0.32–0.83) 0.30 0.39 (0.16–0.93) 0.64 (0.32–1.30) 0.38
Abbreviations: HR: hazard ratio, TTP: time to progression, iTILs: intratumoral tumor infiltrating lymphocytes, sTILs: stromal tumor infiltrating lymphocytes, HE: 
hematoxylin-eosin, TAM: tumor associated macrophages.
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group of patients. There are several ongoing trials combining 
docetaxel or paclitaxel with other immune therapies and in 
combination with one or more other chemotherapy options 
(clinicaltrials.gov: NCT03639948, NCT00179309, 
NCT03894007)).[2,55,56] It is, however, important to note that 
the Impassion 131 trial, treating metastatic TNBC with atezo-
lizumab and paclitaxel as first-line treatment, has not yet 
shown a benefit of adding atezolizumab. The Impassion 131 
trial was done in a patient population quite similar to that in 
Impassion 130, but with a different study design and using 
paclitaxel instead of nab-paclitaxel.16
There are also several trials underway using regimens con-
taining gemcitabine in combination with checkpoint inhibitors 
and other chemotherapy treatments.2,55 However, our results 
suggest that a addition of a second chemotherapy drug may not 
translate into clinical benefit despite presence of 
a demonstrable tumor immune reaction. This may be an 
important consideration for planning future trials, as patients 
may be spared from treatment with several different che-
motherapies given in addition to immune therapy.
Strengths and limitations
Strengths of our study include use of material from 
a randomized clinical trial, a prespecified statistical plan, 
and validated biomarkers with prespecified cut-points in 
a formal prospective-retrospective design. However, our 
study also has important limitations. Our tumor material 
originated from the primary surgery of the patients, but the 
study intervention happened in the advanced setting, after 
patients had received systemic treatment and radiotherapy. 
Our study did not include tissue from the recurrences or 
metastases. Studies have shown that hormone receptors and 
HER2 status may change between primary tumors and their 
subsequent metastases.57 The biological and clinical signifi-
cance of receptor conversion in the context of the TME is 
not known. Heterogeneity may exist between the immune 
profiles of the primary and metastatic lesions and charac-
terization of metastatic lesions may provide insights for 
guiding the course of systemic therapies.58 However, studies 
including biopsies of primary and matched metastatic sites 
have shown that though the absolute lymphocyte counts 
may decline in the latter lesions, the distribution of T and 
B cell subsets in metastatic sites closely approximate that of 
the primary tumor. These observations suggest that the 
primary tumor may in fact drive the immune cell niche 
in metastatic sites.59–62 From a clinical perspective, it is 
important to note that the biomarker study on IMpassion- 
130 trial samples demonstrated that despite lower preva-
lence of PD-L1 in metastatic samples, there was no differ-
ence in the treatment efficacy with respect to biomarker 
expression in the primary or metastatic sites.62 However, 
further prospective, validation studies with clinical outcome 
are warranted.
Figure 2. Time to progression (TTP) and associations with FOXP-3 iTILs levels and treatment arm in the SBG0102 trial population (A+B) and in the nonluminalsubtypes (C 
+D). A. TTP for the FOXP3 iTILs low group, stratified by treatment with docetaxel or docetaxel + gemcitabine (DG), B. TTP for theFOXP3 iTILs high group, stratified by 
treatment with docetaxel or docetaxel + gemcitabine, C. TTP for the FOXP3 iTILs low non-luminal group, stratifiedby treatment with docetaxel or docetaxel + 
gemcitabine. D. TTP for the FOXP3 iTILs high non-luminal group, stratified by treatment with docetaxel orDG. Corresponding figures for overall survival can be seen in 
Supplementary Figure S4. iTILs: intratumoral tumor infiltrating lymphocytes.
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Contrary to the original trial from which the material used 
in this study was taken, there was a significant benefit of GD vs 
D for the overall cohort (Supplementary Table S2). However, 
the difference in treatment effect is most likely random, and 
survival estimates differ only slightly from the original study.30
Our study included all intrinsic breast cancer subtypes and 
was not powered to investigate the basal-like + CD8 high group 
alone, the group that would probably be the most likely to show 
prognostic significance of immune-related biomarkers. This 
was further supported by our finding that FOXP3 sTILs did 
have prognostic significance when adjusted for all four PAM50 
subtypes, but not when looking at the combined non-luminal 
subtypes HER2E and basal-like together.
For evaluation of biomarkers, we chose to distinguish 
between lymphocytes in the peritumoral stroma and intratu-
moral lymphocytes. Evaluation of stromal TILs is standard 
when evaluating TILs on HHE-stainedslides, mainly because 
(blue) lymphocytes are easier to identify against a (pink) 
stromal background than against a (blue) carcinoma cell 
background, leading to increased interobserver 
reproducibility.63 We chose CD8 iTILs as our primary bio-
marker as, from a biological standpoint, TILs that are in 
direct contact with tumor cells should be the most significant 
in the tumor-cytotoxic immune cell interaction, and immu-
nohistochemically brown-stained intratumoral TILs are read-
ily identifiable within carcinoma cell nests. However, we 
found in our study that CD8 sTILs, present in greater num-
bers and in a greater fraction of cases than iTILs, were 
significantly prognostic for our primary endpoint of TTP, 
whereas CD8 iTILs were not. The best method for evaluating 
TILs immunohistochemically remains controversial, and it is 
possible that we made a suboptimal choice of primary 
biomarker.
Finally, we used TMAs in our study. Advantages of TMAs 
are that a large number of tumor samples can be stained for 
biomarkers under very similar conditions, ensuring a uniform 
technical result. Also, evaluation can be more standardized 
when looking at smaller sections of tumor, than when looking 
at a whole tumor slide. Disadvantages of TMAs relate mainly to 
only looking at a very small section of tumor, which can be an 
issue if biomarkers are heterogeneously expressed. In our 
sstudy,we used duplicate 2 mm cores, which increase the area 
investigated somewhat from the more commonly used 0.6 mm 
or 1 mm cores.
Conclusion
Evidence suggests that effects of conventional chemotherapy 
are, in part, mediated through modulation of the tumor 
microenvironment. Gemcitabine in particular has been 
shown to affect specific immune cell types in the tumor 
microenvironment, raising the hypothesis that the degree 
and type of inflammation could be predictive of treatment 
effect. Using a formal prospective-retrospective study design, 
we tested this in material from a clinical trial that randomized 
patients to docetaxel or docetaxel + gemcitabine. For our 
biomarkers tied to cytotoxic T-cell immune response, we 
did not find that levels of our primary biomarker (CD8+ intra-
tumoral T-cells) were predictive of treatment response. Only 
in a subgroup analysis of FOXP3+ lymphocytes in non- 
luminal breast cancers was a significant predictive effect 
observed. CD163, a marker of the innate immune system 
showed borderline significance, indicating that further studies 
investigating predictive capacity of the innate immune system 
are warranted. Overall, our results imply that adding several 
types of immune stimulating conventional chemotherapy 
may not enhance immune benefits. These results may be 
significant for future immunotherapy trials combining one 
or more conventional types of chemotherapy with immune 
therapy.
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